Evidence map›Paper›PMID 33916399›Full record

ArticleInternational journal of environmental research and public health2021

SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan.

Tatsuya Yoshihara, Kazuya Ito, Masayoshi Zaitsu, Eunhee Chung, Izumi Aoyagi, Yoshikazu Kaji, Tomomi Tsuru, Takuma Yonemura, Koji Yamaguchi, Shinichi Nakayama and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Tatsuya YoshiharaClinical Research Center, SOUSEIKAI Fukuoka Mirai Hospital, Kashiiteriha 3-5-1, Higashi-ku, Fukuoka 813-0017, Japan.ORCID 0000-0002-5065-7356
Kazuya ItoSOUSEIKAI Clinical Epidemiological Research Center, Kashiiteriha 3-5-1, Higashi-ku, Fukuoka 813-0017, Japan.
Masayoshi ZaitsuDepartment of Public Health, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan.ORCID 0000-0001-7616-355X
Eunhee ChungSOUSEIKAI Global Clinical Research Center, Kashiiteriha 3-5-1, Higashi-ku, Fukuoka 813-0017, Japan.
Izumi AoyagiDepartment of Internal Medicine, SOUSEIKAI Fukuoka Mirai Hospital, Kashiiteriha 3-5-1, Higashi-ku, Fukuoka 813-0017, Japan.
Yoshikazu KajiSOUSEIKAI Hakata Clinic, 6-18 Tenyamachi, Hakata-ku, Fukuoka 812-0025, Japan.
Tomomi TsuruSOUSEIKAI PS Clinic, 6-18 Tenyamachi, Hakata-ku, Fukuoka 812-0025, Japan.
Takuma YonemuraSOUSEIKAI Sumida Hospital, 1-29-1, Honjo, Sumida-ku, Tokyo 130-0004, Japan.
Koji YamaguchiSOUSEIKAI Nishikumamoto Hospital, 1012 Koga, Tomiaimachi, Minami-ku, Kumamoto 861-4157, Japan.
Shinichi NakayamaSOUSEIKAI Miyata Hospital, 1636 Honjo, Miyawaka, Fukuoka 823-0003, Japan.
Yosuke TanakaSOUSEIKAI Kanenokuma Hospital, 3-24-16 Kanenokuma, Hakata-ku, Fukuoka 812-0863, Japan.
Nobuo YurinoSOUSEIKAI Shinyoshizuka Hospital, 7-6-29, Yoshizuka, Hakata-ku, Fukuoka 812-0041, Japan.
Hideki KoyanagiSOUSEIKAI Dodo Clinic, 1-31-13, Nakaikegami, Ota-ku, Tokyo 146-0081, Japan.
Shunji MatsukiClinical Research Center, SOUSEIKAI Fukuoka Mirai Hospital, Kashiiteriha 3-5-1, Higashi-ku, Fukuoka 813-0017, Japan.
Ryuji UraeSOUSEIKAI, 3-5-1 Kashiiteriha, Higashi-ku, Fukuoka 813-0017, Japan.
Shin IrieSOUSEIKAI, 3-5-1 Kashiiteriha, Higashi-ku, Fukuoka 813-0017, Japan.
SOUSEIKAI Global Clinical Research Center · JPMirai Hospital · JPCollege of Healthcare Management · JPDokkyo Medical University · JPMiyata Eye Hospital · JPSaiseikai Kumamoto Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. In general, healthcare workers are considered to be at higher risk of COVID-19 infection. However, the prevalence of COVID-19 among healthcare workers in Japan is not well characterized. In this study, we aimed to examine the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among 2160 healthcare workers in hospitals and clinics that are not designated to treat COVID-19 patients in Japan. The prevalence of SARS-CoV-2 immunoglobulin G was 1.2% in August and October 2020 (during and after the second wave of the pandemic in Japan), which is relatively higher than that in the general population in Japan (0.03-0.91%). Because of the higher risk of COVID-19 infection, healthcare workers should be the top priority for further social support and vaccination against SARS-CoV-2.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralHealth PersonnelHospitals, GeneralHumansJapanSeroepidemiologic StudiesAntibodies, ViralantibodyCOVID-19healthcare workersSARS-CoV-2seroprevalence

Identifiers

PMID33916399
PMCPMC8038556
OpenAlexW3147116428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.